SC orders government to cap non-patented medicine prices
Business conditions in India are mixed today. The rupee's rebound after RBI measures offers relief to importers, but the stock market's significant loss highlights ongoing volatility. The Supreme Court's order to cap non-patented medicine prices will impact the pharmaceutical sector, requiring companies to adjust pricing strategies.
The Supreme Court of India has directed the government to impose a cap on the prices of non-patented medicines, according to the Times of India. This decision aims to make essential drugs more affordable and accessible to the public. The court's order requires the government to submit a compliance report within six months, detailing the implementation of the price cap.
Impact Pharmaceutical companies must adjust pricing strategies for non-patented drugs, affecting revenue.